Eli Lilly says FDA delays approval of Alzheimer’s drug in surprise move
The FDA plans to call a last-minute meeting of its outside advisors to further review the Eli Lilly Alzheimer's treatment's
Read MoreThe FDA plans to call a last-minute meeting of its outside advisors to further review the Eli Lilly Alzheimer's treatment's
Read MoreThe tech-heavy index closed at its first record high in more than two years on Thursday. Source link
Read MoreThe rollout of Alzheimer's treatment Leqembi from Biogen is going slower than expected, providing a read-through for Club stock Eli
Read MoreThese are the stocks posting the largest moves in midday trading. Source link
Read MoreThe 5,000 milestone is psychologically significant for investors, who are weighing whether stocks have further upside from here. Source link
Read MoreThe investment bank's chief U.S. equity strategist says the risk of recession will be higher than normal next year —
Read MoreEisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the
Read MoreTake a look at some of the most oversold and overbought stocks in the S&P 500 this week. Source link
Read MoreThe Dow Jones Industrial Average is set to close out a 10-day winning streak on Friday. Source link
Read More